Literature DB >> 19639995

6-methyl-2,4-disubstituted pyridazin-3(2H)-ones: a novel class of small-molecule agonists for formyl peptide receptors.

Agostino Cilibrizzi1, Mark T Quinn, Liliya N Kirpotina, Igor A Schepetkin, Jeff Holderness, Richard D Ye, Marie-Josephe Rabiet, Claudio Biancalani, Nicoletta Cesari, Alessia Graziano, Claudia Vergelli, Stefano Pieretti, Vittorio Dal Piaz, Maria Paola Giovannoni.   

Abstract

Following a ligand-based drug design approach, a potent mixed formyl peptide receptor 1 (FPR1) and formyl peptide receptor-like 1 (FPRL1) agonist (14a) and a potent and specific FPRL1 agonist (14x) were identified. These compounds belong to a large series of pyridazin-3(2H)-one derivatives substituted with a methyl group at position 6 and a methoxy benzyl at position 4. At position 2, an acetamide side chain is essential for activity. Likewise, the presence of lipophilic and/or electronegative substituents in the position para to the aryl group at the end of the chain plays a critical role for activity. Affinity for FPR1 receptors was evaluated by measuring intracellular calcium flux in HL-60 cells transfected with FPR1, FPRL1, and FPRL2. Agonists were able to activate intracellular calcium mobilization and chemotaxis in human neutrophils. The most potent chemotactic agent (EC(50) = 0.6 microM) was the mixed FPR/FPRL1 agonist 14h.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19639995      PMCID: PMC2888720          DOI: 10.1021/jm900592h

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  23 in total

1.  Integration of virtual screening with high-throughput flow cytometry to identify novel small molecule formylpeptide receptor antagonists.

Authors:  Bruce S Edwards; Cristian Bologa; Susan M Young; Konstantin V Balakin; Eric R Prossnitz; Nikolay P Savchuck; Larry A Sklar; Tudor I Oprea
Journal:  Mol Pharmacol       Date:  2005-08-23       Impact factor: 4.436

2.  The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli.

Authors:  E Schiffmann; H V Showell; B A Corcoran; P A Ward; E Smith; E L Becker
Journal:  J Immunol       Date:  1975-06       Impact factor: 5.422

3.  Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry.

Authors:  J M Kilby; S Hopkins; T M Venetta; B DiMassimo; G A Cloud; J Y Lee; L Alldredge; E Hunter; D Lambert; D Bolognesi; T Matthews; M R Johnson; M A Nowak; G M Shaw; M S Saag
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

4.  The neurotoxic prion peptide fragment PrP(106-126) is a chemotactic agonist for the G protein-coupled receptor formyl peptide receptor-like 1.

Authors:  Y Le; H Yazawa; W Gong; Z Yu; V J Ferrans; P M Murphy; J M Wang
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

5.  Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation.

Authors:  Y Le; W Gong; B Li; N M Dunlop; W Shen; S B Su; R D Ye; J M Wang
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

6.  Mobilizing lipocortin 1 in adherent human leukocytes downregulates their transmigration.

Authors:  M Perretti; J D Croxtall; S K Wheller; N J Goulding; R Hannon; R J Flower
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

7.  Differential activation of formyl peptide receptor signaling by peptide ligands.

Authors:  Yoe-Sik Bae; Ji Young Song; Youndong Kim; Rong He; Richard D Ye; Jong-Young Kwak; Pann-Ghill Suh; Sung Ho Ryu
Journal:  Mol Pharmacol       Date:  2003-10       Impact factor: 4.436

8.  Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1.

Authors:  Y Le; W Gong; H L Tiffany; A Tumanov; S Nedospasov; W Shen; N M Dunlop; J L Gao; P M Murphy; J J Oppenheim; J M Wang
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

9.  A novel nonpeptide ligand for formyl peptide receptor-like 1.

Authors:  Masakatsu Nanamori; Xiyuan Cheng; Jianghua Mei; Hairong Sang; Yunxia Xuan; Caihong Zhou; Ming-Wei Wang; Richard D Ye
Journal:  Mol Pharmacol       Date:  2004-08-12       Impact factor: 4.436

10.  Impaired antibacterial host defense in mice lacking the N-formylpeptide receptor.

Authors:  J L Gao; E J Lee; P M Murphy
Journal:  J Exp Med       Date:  1999-02-15       Impact factor: 14.307

View more
  23 in total

1.  Inhibition of neutrophil migration in mice by mouse formyl peptide receptors 1 and 2 dual agonist: indication of cross-desensitization in vivo.

Authors:  Yoshitaka Sogawa; Takao Ohyama; Hiroaki Maeda; Kazuki Hirahara
Journal:  Immunology       Date:  2010-10-29       Impact factor: 7.397

2.  Computational structure-activity relationship analysis of small-molecule agonists for human formyl peptide receptors.

Authors:  Andrei I Khlebnikov; Igor A Schepetkin; Mark T Quinn
Journal:  Eur J Med Chem       Date:  2010-09-15       Impact factor: 6.514

3.  Selective agonists and antagonists of formylpeptide receptors: duplex flow cytometry and mixture-based positional scanning libraries.

Authors:  Clemencia Pinilla; Bruce S Edwards; Jon R Appel; Tina Yates-Gibbins; Marc A Giulianotti; Jose L Medina-Franco; Susan M Young; Radleigh G Santos; Larry A Sklar; Richard A Houghten
Journal:  Mol Pharmacol       Date:  2013-06-20       Impact factor: 4.436

Review 4.  Development of small molecule non-peptide formyl peptide receptor (FPR) ligands and molecular modeling of their recognition.

Authors:  I A Schepetkin; A I Khlebnikov; M P Giovannoni; L N Kirpotina; A Cilibrizzi; M T Quinn
Journal:  Curr Med Chem       Date:  2014       Impact factor: 4.530

5.  Synthesis of Five- and Six-Membered N-Phenylacetamido Substituted Heterocycles as Formyl Peptide Receptor Agonists.

Authors:  Claudia Vergelli; Igor A Schepetkin; Giovanna Ciciani; Agostino Cilibrizzi; Letizia Crocetti; Maria Paola Giovannoni; Gabriella Guerrini; Antonella Iacovone; Liliya N Kirpotina; Richard D Ye; Mark T Quinn
Journal:  Drug Dev Res       Date:  2016-11-18       Impact factor: 4.360

6.  Synthesis, enantioresolution, and activity profile of chiral 6-methyl-2,4-disubstituted pyridazin-3(2H)-ones as potent N-formyl peptide receptor agonists.

Authors:  Agostino Cilibrizzi; Igor A Schepetkin; Gianluca Bartolucci; Letizia Crocetti; Vittorio Dal Piaz; Maria Paola Giovannoni; Alessia Graziano; Liliya N Kirpotina; Mark T Quinn; Claudia Vergelli
Journal:  Bioorg Med Chem       Date:  2012-04-27       Impact factor: 3.641

7.  Novel formyl peptide receptor (FPR) agonists with pyridinone and pyrimidindione scaffolds that are potentially useful for the treatment of rheumatoid arthritis.

Authors:  Letizia Crocetti; Claudia Vergelli; Gabriella Guerrini; Niccolò Cantini; Liliya N Kirpotina; Igor A Schepetkin; Mark T Quinn; Carmen Parisio; Lorenzo Di Cesare Mannelli; Carla Ghelardini; Maria Paola Giovannoni
Journal:  Bioorg Chem       Date:  2020-04-28       Impact factor: 5.275

8.  2-Arylacetamido-4-phenylamino-5-substituted pyridazinones as formyl peptide receptors agonists.

Authors:  Claudia Vergelli; Igor A Schepetkin; Giovanna Ciciani; Agostino Cilibrizzi; Letizia Crocetti; Maria Paola Giovannoni; Gabriella Guerrini; Antonella Iacovone; Liliya N Kirpotina; Andrei I Khlebnikov; Richard D Ye; Mark T Quinn
Journal:  Bioorg Med Chem       Date:  2016-04-08       Impact factor: 3.641

9.  3-(1H-indol-3-yl)-2-[3-(4-nitrophenyl)ureido]propanamide enantiomers with human formyl-peptide receptor agonist activity: molecular modeling of chiral recognition by FPR2.

Authors:  Igor A Schepetkin; Liliya N Kirpotina; Andrei I Khlebnikov; Marcello Leopoldo; Ermelinda Lucente; Enza Lacivita; Paola De Giorgio; Mark T Quinn
Journal:  Biochem Pharmacol       Date:  2012-12-03       Impact factor: 5.858

10.  Further studies on 2-arylacetamide pyridazin-3(2H)-ones: design, synthesis and evaluation of 4,6-disubstituted analogs as formyl peptide receptors (FPRs) agonists.

Authors:  Maria Paola Giovannoni; Igor A Schepetkin; Agostino Cilibrizzi; Letizia Crocetti; Andrei I Khlebnikov; Claes Dahlgren; Alessia Graziano; Vittorio Dal Piaz; Liliya N Kirpotina; Serena Zerbinati; Claudia Vergelli; Mark T Quinn
Journal:  Eur J Med Chem       Date:  2013-04-08       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.